Home

Sekar Kathiresan

CIK 1864112 · Chief Executive Officer · last filed 2025-09-24

Sekar Kathiresan is a Chief Executive Officer who has filed 27 SEC Form 4 insider transactions across 3 companies since 2021. The most recent filing, for RLAY, was dated Jul 21, 2026. Across all open-market trades the lifetime net is −$11.2M, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

3

Total Filings

27

Lifetime Open-Market Net

-$11.18M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
MAZE Director — $27.88 — $0 1 2025-09-24
Verve Therapeutics, Inc. (VERV) Delisted Chief Executive Officer 0 $11.13 $0 -$11.18M 17 2025-07-28
RLAY Director — $18.29 — $0 4 2025-06-06

Recent Filings

27 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-21 RLAY Notice (144) −30,000 -$594.4K EDGAR
2026-07-20 RLAY Notice (144) −66,055 -$1.29M EDGAR
2026-01-16 MAZE Notice (144) −29,772 -$1.21M EDGAR
2025-12-04 MAZE Notice (144) −10,000 -$425.4K EDGAR
2025-11-21 MAZE Notice (144) −27,500 -$984.6K EDGAR
2025-09-24 MAZE Grant (A) — $0 EDGAR
2025-07-28 Verve Therapeutics, Inc. (VERV) Delisted Mixed −700,425 $0 EDGAR
2025-06-06 RLAY Grant (A) — $0 EDGAR
2025-04-03 Verve Therapeutics, Inc. (VERV) Delisted Mixed +23,178 -$40.8K EDGAR
2025-01-10 Verve Therapeutics, Inc. (VERV) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 27
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.